Aclaris Therapeutics (ACRS) Current Assets (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Current Assets of $110.2 million for Q1 2026, up 1.32% year-over-year from $108.8 million in Q1 2025, and up 14.45% quarter-over-quarter from $96.3 million in Q4 2025.
Aclaris Therapeutics (ACRS) Current Assets (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Current Assets history runs 13 years deep, the most recent figure standing at $110.2 million for Q1 2026.
- In Q1 2026, Current Assets rose 1.32% year-over-year to $110.2 million; the TTM figure through Mar 2026 stood at $110.2 million (up 1.32% YoY), while the FY2025 annual figure was $96.3 million, down 23.53% from the prior year.
- Current Assets for Q1 2026 stood at $110.2 million, up from $96.3 million in the prior quarter.
- The five-year high for Current Assets was $259.4 million in Q2 2022, with the low at $96.3 million in Q4 2025.
- The 5-year median for Current Assets is $128.9 million (2023), against an average of $149.4 million.
- The sharpest annual moves came in 2022 and 2023: Current Assets jumped 41.92% in 2022, then sank 52.03% in 2023.
- Aclaris Therapeutics' Current Assets stood at $231.6 million in 2022, then tumbled by 44.35% to $128.9 million in 2023, then decreased by 2.25% to $126.0 million in 2024, then dropped by 23.53% to $96.3 million in 2025, then grew by 14.45% to $110.2 million in 2026.
- Business Quant data shows ACRS's Current Assets at $110.2 million in Q1 2026, $96.3 million in Q4 2025, and $100.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 97.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.77 Mn |
| Mar 31, 2026 | 110.23 Mn |
| Dec 31, 2025 | 96.32 Mn |
| Sep 30, 2025 | 100.59 Mn |
| Jun 30, 2025 | 104.20 Mn |
| Mar 31, 2025 | 108.79 Mn |
| Dec 31, 2024 | 125.95 Mn |
| Sep 30, 2024 | 132.33 Mn |
| Jun 30, 2024 | 117.64 Mn |
| Mar 31, 2024 | 135.34 Mn |
| Dec 31, 2023 | 128.86 Mn |
| Sep 30, 2023 | 123.07 Mn |
| Jun 30, 2023 | 132.94 Mn |
| Mar 31, 2023 | 184.36 Mn |
| Dec 31, 2022 | 231.55 Mn |
| Sep 30, 2022 | 256.57 Mn |
| Jun 30, 2022 | 259.35 Mn |
| Mar 31, 2022 | 190.88 Mn |
| Dec 31, 2021 | 205.03 Mn |
| Sep 30, 2021 | 205.78 Mn |